Publicacións (59) Publicacións de José Luis Bello López

2020

  1. Novel Mutation Hotspots within Non-Coding Regulatory Regions of the Chronic Lymphocytic Leukemia Genome

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia

    Journal of Oncology, Vol. 2019

  2. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

  3. Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia

    Blood cancer journal

  4. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

  5. New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data

    Frontiers in Genetics, Vol. 10

  6. The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

    BMC Cancer, Vol. 19, Núm. 1

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

  2. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

    British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2015

  1. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69

2014

  1. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

    Tumori, Vol. 100, Núm. 2, pp. 225-231

  2. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  3. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  4. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

  5. Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use

    Leukemia and Lymphoma

2013

  1. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

    Medical Mycology, Vol. 51, Núm. 2, pp. 150-154

  2. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

  3. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

    Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952